Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 273,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "f1ad6c33-9a6b-46d6-9676-1dc6ba7ce0b1",
"title": "ImmunoPrecise、第1四半期の業績は好悪混在、将来の成長に期待 執筆： Investing.com",
"description": "ImmunoPrecise、第1四半期の業績は好悪混在、将来の成長に期待",
"keywords": "",
"snippet": "\n\n\n\n治療用抗体の発見を行う総合サービス企業であるImmunoPrecise Antibodies Ltd. (IPA)は、2024年7月31日に2025年度第1四半期の財?...",
"url": "https://jp.investing.com/news/stock-market-news/article-93CH-869457",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPEB210AE_L.jpg",
"language": "ja",
"published_at": "2024-09-17T14:34:12.000000Z",
"source": "jp.investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "IPATF",
"name": "Immunoprecise Antibodies Ltd",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 46.35251,
"sentiment_score": null,
"highlights": [
{
"highlight": "治療用抗体の発見を行う総合サービス企業である<em>ImmunoPrecise</em> <em>Antibodies</em> <em>Ltd</em>. (IPA)は、2024年7月31日に2025年度第1四半期の財務結果を発表しました。同社の前年同期比の収益は若干減少し、5.3百万ドルと7.5%の減少となりました。\n\n\n\n\n\nしかし、これは前年度第1四半期と比較すると12%の増加となっています。ImmunoPreciseのCEOであるJennifer Bath博士とCFOのKristin Taylorが決算説明会を主導し、同社の業績と戦略的計画について説明しました。その中には、抗体の発見と開発に使用するAI駆動型のLENSaiプラットフォームの活用も含まれています。",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ImmunoPrecise</em> <em>Antibodies</em> <em>Ltd</em>. (IPA)は、市場の課題に直面しながらも回復力を示し、より強固な財務的未来に向けた戦略的な動きを見せています。同社のLENSaiのようなAI駆動型プラットフォームと戦略的ライセンス契約への注力は、バイオテク分野での持続的な成長と回復への道を開く可能性があります。連邦準備制度理事会による潜在的な利下げを市場が予想する中、ImmunoPreciseは将来の成功に向けてパイプラインの強化と資産の最適化に注力し続けています。\n\n\n\n\n\nInvestingProの洞察\n\n\n\n\n\n<em>ImmunoPrecise</em> <em>Antibodies</em> <em>Ltd</em>.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "IPA.V",
"name": "ImmunoPrecise Antibodies Ltd.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.879124,
"sentiment_score": null,
"highlights": [
{
"highlight": "治療用抗体の発見を行う総合サービス企業である<em>ImmunoPrecise</em> <em>Antibodies</em> <em>Ltd</em>. (IPA)は、2024年7月31日に2025年度第1四半期の財務結果を発表しました。同社の前年同期比の収益は若干減少し、5.3百万ドルと7.5%の減少となりました。\n\n\n\n\n\nしかし、これは前年度第1四半期と比較すると12%の増加となっています。ImmunoPreciseのCEOであるJennifer Bath博士とCFOのKristin Taylorが決算説明会を主導し、同社の業績と戦略的計画について説明しました。その中には、抗体の発見と開発に使用するAI駆動型のLENSaiプラットフォームの活用も含まれています。",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ImmunoPrecise</em> <em>Antibodies</em> <em>Ltd</em>. (IPA)は、市場の課題に直面しながらも回復力を示し、より強固な財務的未来に向けた戦略的な動きを見せています。同社のLENSaiのようなAI駆動型プラットフォームと戦略的ライセンス契約への注力は、バイオテク分野での持続的な成長と回復への道を開く可能性があります。連邦準備制度理事会による潜在的な利下げを市場が予想する中、ImmunoPreciseは将来の成功に向けてパイプラインの強化と資産の最適化に注力し続けています。\n\n\n\n\n\nInvestingProの洞察\n\n\n\n\n\n<em>ImmunoPrecise</em> <em>Antibodies</em> <em>Ltd</em>.",
"sentiment": null,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "ee2e4a20-43b1-456e-8ced-1d6a609e18b5",
"title": "Compass Minerals, Torrid Holdings, Icahn Enterprises, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday - Compass Minerals Intl (NYSE:CMP)",
"description": "",
"keywords": "",
"snippet": "U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Monday.\n\nShares of Compass Minerals International, Inc. CMP rose sharply during Tu...",
"url": "https://www.benzinga.com/news/24/09/40901313/compass-minerals-torrid-holdings-icahn-enterprises-hewlett-packard-enterprise-and-other-big-stocks-m",
"image_url": "https://cdn.benzinga.com/files/images/story/2024/09/17/movers-image_1.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-09-17T14:22:18.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "TDOC",
"name": "Teladoc Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.819529,
"sentiment_score": 0.5267,
"highlights": [
{
"highlight": "<em>Teladoc</em> <em>Health</em>, <em>Inc</em> . TDOC jumped 10.4% to $9.01.\n\n. jumped 10.4% to $9.01. Definitive Healthcare Corp . DH shares rose 9.5% to $4.86. BTIG analyst David Larsen initiated coverage on Definitive Healthcare with a Buy rating and announced a price target of $7.\n\n. shares rose 9.5% to $4.86.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "97716ef0-9830-487f-9e34-b6d5219b7aa3",
"title": "Unpacking the Latest Options Trading Trends in Eli Lilly - Eli Lilly (NYSE:LLY)",
"description": "",
"keywords": "",
"snippet": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly.\n\nLooking at options history for Eli Lilly LLY we detected 30 trades.\n\nI...",
"url": "https://www.benzinga.com/insights/options/24/09/40901160/unpacking-the-latest-options-trading-trends-in-eli-lilly",
"image_url": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-09-17T14:16:12.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "LLY",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 44.931366,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Unpacking the Latest Options Trading Trends in Eli Lilly - Eli Lilly (<em>NYSE:LLY</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "e775b8ae-17ea-4f7a-985d-41d02a968245",
"title": "Pfizer Unusual Options Activity - Pfizer (NYSE:PFE)",
"description": "",
"keywords": "",
"snippet": "Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 8 unusual trades.\n\nDelving into the det...",
"url": "https://www.benzinga.com/insights/options/24/09/40900709/pfizer-unusual-options-activity",
"image_url": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-09-17T14:01:44.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.41257,
"sentiment_score": 0.091033,
"highlights": [
{
"highlight": "Financial giants have made a conspicuous bearish move on <em>Pfizer</em>. Our analysis of options history for <em>Pfizer</em> PFE revealed 8 unusual trades.\n\nDelving into the details, we found 37% of traders were bullish, while 50% showed bearish tendencies.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Projected Price Targets\n\nAnalyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $30.0 for <em>Pfizer</em> during the past quarter.\n\nVolume & Open Interest Development\n\nLooking at the volume and open interest is a powerful move while trading options.",
"sentiment": 0.8957,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> 30-Day Option Volume & Interest Snapshot\n\nBiggest Options Spotted:\n\nSymbol PUT/CALL Trade Type Sentiment Exp.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "SWEEP BULLISH 10/04/24 $4.15 $4.05 $4.15 $26.00 $83.0K 301 0 PFE PUT SWEEP BULLISH 01/15/27 $6.9 $4.4 $4.4 $30.00 $66.0K 20 0 PFE PUT TRADE BULLISH 01/16/26 $3.45 $3.4 $3.4 $30.00 $51.0K 30.7K 0 PFE CALL SWEEP BEARISH 10/18/24 $0.89 $0.87 $0.87 $30.00 $50.4K 22.2K 887 PFE CALL SWEEP NEUTRAL 01/16/26 $15.75 $14.75 $15.3 $15.00 $30.5K 565 20\n\nAbout <em>Pfizer</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.\n\nPfizer's Current Market Status\n\nWith a volume of 1,860,933, the price of PFE is down -0.25% at $30.0.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "What The Experts Say On <em>Pfizer</em>\n\nIn the last month, 3 experts released ratings on this stock with an average target price of $45.0.\n\nAn analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.\n\nAn analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "If you want to stay updated on the latest options trades for <em>Pfizer</em>, Benzinga Pro gives you real-time options trades alerts.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> Unusual Options Activity - <em>Pfizer</em> (<em>NYSE:PFE</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "7b8bcc04-9d76-405f-b77c-6f218021bd01",
"title": "AIMD stock touches 52-week low at $0.45 amid market challenges By Investing.com",
"description": "AIMD stock touches 52-week low at $0.45 amid market challenges",
"keywords": "",
"snippet": "In a challenging market environment, AIMD stock has reached a new 52-week low, dipping to $0.45. This significant downturn reflects a broader trend for the comp...",
"url": "https://www.investing.com/news/company-news/aimd-stock-touches-52week-low-at-045-amid-market-challenges-93CH-3619660",
"image_url": "https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png",
"language": "en",
"published_at": "2024-09-17T13:42:57.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "AIMD",
"name": "Ainos, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 88.80386,
"sentiment_score": 0.3392,
"highlights": [
{
"highlight": "In a challenging market environment, <em>AIMD</em> stock has reached a new 52-week low, dipping to $0.45. This significant downturn reflects a broader trend for the company, which has seen its value decrease by 85.78% over the past year.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Investors are closely monitoring <em>AIMD</em> as it navigates through these turbulent financial waters, with the hope that the company's strategies will steer it back towards more favorable tides.",
"sentiment": 0.7402,
"highlighted_in": "main_text"
},
{
"highlight": "The 52-week low serves as a critical juncture for <em>AIMD</em>, marking a period of intense scrutiny and potential reassessment of the company's long-term growth prospects.\n\n\n\n\n\nIn other recent news, <em>Ainos</em>, <em>Inc</em>. has made significant strides in various areas.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Moreover, <em>Ainos</em> has secured a patent in Taiwan for VELDONA®, an antiviral drug targeting coronavirus infections.\n\nThe company's AI Nose technology has also shown impressive results, achieving a 79% accuracy rate in detecting volatile organic compounds in Japanese semiconductor factories.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Ainos</em> has also acquired exclusive licenses for 10 invention patents from Taiwan Carbon Nano Technology, valued at approximately $5.4 million, likely to bolster the company's AI Nose and point-of-care testing technologies.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "However, <em>Ainos</em> faces a potential delisting from the Nasdaq due to its stock price falling below the required minimum bid price, and it has been given a grace period until January 13, 2025, to regain compliance. These are among the recent developments at <em>Ainos</em>, <em>Inc</em>.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "These figures underscore the challenges <em>AIMD</em> faces in generating sales and expanding its market presence.\n\nThe InvestingPro Tips highlight critical areas of concern for investors. <em>AIMD</em> is quickly burning through cash and suffers from weak gross profit margins, which are evident from the -316.61% gross profit margin reported.",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "For those considering <em>AIMD</em> as an investment opportunity, it's important to note that the company does not pay dividends, which might deter income-focused investors. Additionally, the stock is trading near its 52-week low, which could be a point of interest for value investors looking for potential turnaround candidates.",
"sentiment": 0.7916,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro offers additional insights and tips for <em>AIMD</em>, which can be found at https://www.investing.com/pro/<em>AIMD</em>. These tips may provide further guidance for investors trying to navigate the current conditions of <em>AIMD</em> stock.\n\nThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AIMD</em> stock touches 52-week low at $0.45 amid market challenges By Investing.com",
"sentiment": -0.2023,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "a2df7677-4304-4c8a-86fd-25bd5d150605",
"title": "Mental Health Market to Surpass Market Valuation of USD 544.63 Billion by 2031 | SkyQuest Technology",
"description": "Global Mental Health Market size was valued at USD 413.60 billion in 2023 to USD 544.63 billion by 2031, at a CAGR of 3.5% during the forecast period...",
"keywords": "SkyQuest Technology Consulting Pvt. Ltd., Mental Health Market, Mental Health Market Share, Mental Health Market Trends, Mental Health Market Size, Mental Health",
"snippet": "Westford, USA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Mental Health Market will reach a value of USD 544.63 Billion by 2031, with ...",
"url": "https://www.globenewswire.com/news-release/2024/09/17/2947432/0/en/Mental-Health-Market-to-Surpass-Market-Valuation-of-USD-544-63-Billion-by-2031-SkyQuest-Technology.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/c673c6fa-f0e7-47bf-8490-fe528c593820",
"language": "en",
"published_at": "2024-09-17T12:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMGN",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.189053,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(India)\n\nAlkermes plc (Ireland)\n\n<em>Amgen</em> <em>Inc</em>. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ALKS",
"name": "Alkermes plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.344847,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(India)\n\n<em>Alkermes</em> <em>plc</em> (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 21.790287,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\n<em>Gilead</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JAZZ",
"name": "Jazz Pharmaceuticals plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.871456,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "(US)\n\nHikma Pharmaceuticals PLC (UK)\n\n<em>Jazz</em> <em>Pharmaceuticals</em> <em>plc</em> (Ireland)\n\nTake Action Now: Secure Your Mental Health Market Today - https://www.skyquestt.com/buy-now/mental-health-market\n\nKey Questions Answered in Global Mental Health Market Report\n\nBy 2031, how much is the global mental health market expected to be worth?",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBV",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.035221,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(Israel)\n\n<em>AbbVie</em> <em>Inc</em>. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH. Lundbeck A/S (Denmark)\n\nSun Pharmaceutical Industries Ltd. (India)\n\nAlkermes plc (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.817316,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nJohnson & Johnson (US)\n\n<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em> (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\nMerck & Co., Inc. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBV34.SA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.035006,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(Israel)\n\n<em>AbbVie</em> <em>Inc</em>. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH. Lundbeck A/S (Denmark)\n\nSun Pharmaceutical Industries Ltd. (India)\n\nAlkermes plc (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LILY34.SA",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.81725,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nJohnson & Johnson (US)\n\n<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em> (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\nMerck & Co., Inc. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TAKP34.SA",
"name": "Takeda Pharmaceutical Company Limited",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.269968,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\n<em>Takeda</em> <em>Pharmaceutical</em> <em>Company</em> <em>Limited</em> (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.789822,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nJohnson & Johnson (US)\n\nEli Lilly and Company (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\n<em>Merck</em> & <em>Co</em>., <em>Inc</em>. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TAK",
"name": "Takeda Pharmaceutical Company Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.269485,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\n<em>Takeda</em> <em>Pharmaceutical</em> <em>Company</em> <em>Limited</em> (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.330102,
"sentiment_score": -0.2787,
"highlights": [
{
"highlight": "Market Insight\n\nDrivers:\n\nMental Health Awareness in Educational Settings\n\nMental Health Coverage in Insurance Plans\n\nGrowing Demand for Substance Abuse Treatment Programs\n\nRestraints:\n\nStigma Associated with Mental Health Issues\n\nLimited Mental Health Professionals\n\nHigh Cost of Mental Health Treatments\n\nProminent Players in Mental Health Market\n\n<em>Pfizer</em>",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 11.330102,
"sentiment_score": -0.2787,
"highlights": [
{
"highlight": "Market Insight\n\nDrivers:\n\nMental Health Awareness in Educational Settings\n\nMental Health Coverage in Insurance Plans\n\nGrowing Demand for Substance Abuse Treatment Programs\n\nRestraints:\n\nStigma Associated with Mental Health Issues\n\nLimited Mental Health Professionals\n\nHigh Cost of Mental Health Treatments\n\nProminent Players in Mental Health Market\n\n<em>Pfizer</em>",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.075293,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\n<em>Johnson</em> & <em>Johnson</em> (US)\n\nEli Lilly and Company (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\nMerck & Co., Inc. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HLUYY",
"name": "H. Lundbeck A/S",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 25.745491,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\n<em>H</em>. <em>Lundbeck</em> <em>A</em>/<em>S</em> (Denmark)\n\nSun Pharmaceutical Industries Ltd. (India)\n\nAlkermes plc (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "OTSKY",
"name": "Otsuka Holdings Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 29.534813,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\n<em>Otsuka</em> <em>Holdings</em> <em>Co</em>., <em>Ltd</em>. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TKPHF",
"name": "Takeda Pharmaceutical Company Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.270555,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\n<em>Takeda</em> <em>Pharmaceutical</em> <em>Company</em> <em>Limited</em> (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HKMPY",
"name": "Hikma Pharmaceuticals PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.832235,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "(US)\n\n<em>Hikma</em> <em>Pharmaceuticals</em> <em>PLC</em> (UK)\n\nJazz Pharmaceuticals plc (Ireland)\n\nTake Action Now: Secure Your Mental Health Market Today - https://www.skyquestt.com/buy-now/mental-health-market\n\nKey Questions Answered in Global Mental Health Market Report\n\nBy 2031, how much is the global mental health market expected to be worth?",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HLUKF",
"name": "H. Lundbeck A/S",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 25.753155,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\n<em>H</em>. <em>Lundbeck</em> <em>A</em>/<em>S</em> (Denmark)\n\nSun Pharmaceutical Industries Ltd. (India)\n\nAlkermes plc (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HKMPF",
"name": "Hikma Pharmaceuticals PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.831347,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "(US)\n\n<em>Hikma</em> <em>Pharmaceuticals</em> <em>PLC</em> (UK)\n\nJazz Pharmaceuticals plc (Ireland)\n\nTake Action Now: Secure Your Mental Health Market Today - https://www.skyquestt.com/buy-now/mental-health-market\n\nKey Questions Answered in Global Mental Health Market Report\n\nBy 2031, how much is the global mental health market expected to be worth?",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "OTSKF",
"name": "Otsuka Holdings Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 29.533318,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\n<em>Otsuka</em> <em>Holdings</em> <em>Co</em>., <em>Ltd</em>. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SUNPHARMA-BL.NS",
"name": "SUN PHARMACEUTICAL",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "N/A",
"match_score": 15.363342,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Lundbeck A/S (Denmark)\n\n<em>Sun</em> <em>Pharmaceutical</em> Industries Ltd. (India)\n\nAlkermes plc (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DJNJ2.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.074207,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\n<em>Johnson</em> & <em>Johnson</em> (US)\n\nEli Lilly and Company (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\nMerck & Co., Inc. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DJNJ3.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.074207,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\n<em>Johnson</em> & <em>Johnson</em> (US)\n\nEli Lilly and Company (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\nMerck & Co., Inc. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFED.BA",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 11.329759,
"sentiment_score": -0.2787,
"highlights": [
{
"highlight": "Market Insight\n\nDrivers:\n\nMental Health Awareness in Educational Settings\n\nMental Health Coverage in Insurance Plans\n\nGrowing Demand for Substance Abuse Treatment Programs\n\nRestraints:\n\nStigma Associated with Mental Health Issues\n\nLimited Mental Health Professionals\n\nHigh Cost of Mental Health Treatments\n\nProminent Players in Mental Health Market\n\n<em>Pfizer</em>",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMGN.BA",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.187428,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(India)\n\nAlkermes plc (Ireland)\n\n<em>Amgen</em> <em>Inc</em>. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.BA",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.815357,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nJohnson & Johnson (US)\n\n<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em> (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\nMerck & Co., Inc. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBV.BA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 14.037496,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(Israel)\n\n<em>AbbVie</em> <em>Inc</em>. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH. Lundbeck A/S (Denmark)\n\nSun Pharmaceutical Industries Ltd. (India)\n\nAlkermes plc (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRKD.BA",
"name": "MERCK & CO INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 14.792018,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nJohnson & Johnson (US)\n\nEli Lilly and Company (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\n<em>Merck</em> & <em>Co</em>., <em>Inc</em>. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBVD.BA",
"name": "ABBVIE INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 14.037496,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(Israel)\n\n<em>AbbVie</em> <em>Inc</em>. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH. Lundbeck A/S (Denmark)\n\nSun Pharmaceutical Industries Ltd. (India)\n\nAlkermes plc (Ireland)\n\nAmgen Inc. (US)\n\nGilead Sciences, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 19.632046,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\n<em>Gilead</em> <em>Sciences</em>, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 11.329483,
"sentiment_score": -0.2787,
"highlights": [
{
"highlight": "Market Insight\n\nDrivers:\n\nMental Health Awareness in Educational Settings\n\nMental Health Coverage in Insurance Plans\n\nGrowing Demand for Substance Abuse Treatment Programs\n\nRestraints:\n\nStigma Associated with Mental Health Issues\n\nLimited Mental Health Professionals\n\nHigh Cost of Mental Health Treatments\n\nProminent Players in Mental Health Market\n\n<em>Pfizer</em>",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.791062,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nJohnson & Johnson (US)\n\nEli Lilly and Company (US)\n\nBristol-Myers Squibb (US)\n\nGlaxoSmithKline (UK)\n\nAstraZeneca (UK)\n\n<em>Merck</em> & <em>Co</em>., <em>Inc</em>. (US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.SN",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.329483,
"sentiment_score": -0.2787,
"highlights": [
{
"highlight": "Market Insight\n\nDrivers:\n\nMental Health Awareness in Educational Settings\n\nMental Health Coverage in Insurance Plans\n\nGrowing Demand for Substance Abuse Treatment Programs\n\nRestraints:\n\nStigma Associated with Mental Health Issues\n\nLimited Mental Health Professionals\n\nHigh Cost of Mental Health Treatments\n\nProminent Players in Mental Health Market\n\n<em>Pfizer</em>",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "4502.T",
"name": "Takeda Pharmaceutical Company Limited",
"exchange": null,
"exchange_long": null,
"country": "jp",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.267897,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\n<em>Takeda</em> <em>Pharmaceutical</em> <em>Company</em> <em>Limited</em> (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "4578.T",
"name": "Otsuka Holdings Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "jp",
"type": "equity",
"industry": "Healthcare",
"match_score": 29.526161,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "(US)\n\nTakeda Pharmaceutical Company Limited (Japan)\n\n<em>Otsuka</em> <em>Holdings</em> <em>Co</em>., <em>Ltd</em>. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "4502.S",
"name": "Takeda Pharmaceutical Company Limited",
"exchange": null,
"exchange_long": null,
"country": "jp",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.267271,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(US)\n\n<em>Takeda</em> <em>Pharmaceutical</em> <em>Company</em> <em>Limited</em> (Japan)\n\nOtsuka Holdings Co., Ltd. (Japan)\n\nNovartis International AG (Switzerland)\n\nSanofi S.A. (France)\n\nLundbeck A/S (Denmark)\n\nTeva Pharmaceutical Industries Ltd. (Israel)\n\nAbbVie Inc. (US)\n\nBoehringer Ingelheim International GmbH (Germany)\n\nH.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "2a1c428a-35d3-4738-9c69-3c47988f747f",
"title": "Addus HomeCare Corporation (ADUS) Share Price Surged on Solid Result",
"description": "TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2024 investor letter.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nThe ...",
"url": "https://www.insidermonkey.com/blog/addus-homecare-corporation-adus-share-price-surged-on-solid-result-1353995/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/10/13182835/CHE-insidermonkey-1697236113176.jpg",
"language": "en",
"published_at": "2024-09-17T13:30:38.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "ADUS",
"name": "Addus HomeCare Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 184.1838,
"sentiment_score": 0.4215,
"highlights": [
{
"highlight": "<em>Addus</em> <em>HomeCare</em> <em>Corporation</em> (ADUS) Share Price Surged on Solid Result",
"sentiment": 0.4215,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "be949715-df08-4899-8340-b7a499b50ffd",
"title": "Zoetis to Introduce First Cartridge-Based AI-Powered Haematology Analyser",
"description": "Zoetis is introducing Vetscan® OptiCell™ to Australia as it continues to transform diagnostics with its suite of integrated products and services The new haematology analyser offers innovative AI-powered technology for CBC analysis, providing lab quality accuracy1 at the point of care The analyser represents significant time, cost and space savings for veterinarians with minimal maintenance requirements SYDNEY, Sept. 17, 2024 /PRNewswire/ -- Zoetis Inc., the world's leading animal health company, is set to unveil its new haematology analyser Vetscan® OptiCell™, a cartridge-based, AI-powered diagnostic tool for more advanced Complete Blood Count (CBC) analysis. The analyser - to be introduced to Australia later this year - represents a significant leap in technology and offers meaningful time, cost, and space savings for veterinary teams, to enable better patient outcomes and a more efficient clinic workflow.",
"keywords": "Zoetis, to, Introduce, First, Cartridge-Based, AI-Powered, Haematology, Analyser",
"snippet": "Zoetis is introducing Vetscan ® OptiCell™ to Australia as it continues to transform diagnostics with its suite of integrated products and services\n\nOptiCell?...",
"url": "https://www.manilatimes.net/2024/09/17/tmt-newswire/pr-newswire/zoetis-to-introduce-first-cartridge-based-ai-powered-haematology-analyser/1972158",
"image_url": "https://cdn4.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1920&q=100&f=webp&v=1",
"language": "en",
"published_at": "2024-09-17T13:25:27.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "ZTS",
"name": "Zoetis Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.019238,
"sentiment_score": 0.53338,
"highlights": [
{
"highlight": "<em>Zoetis</em> is introducing Vetscan ® OptiCell™ to Australia as it continues to transform diagnostics with its suite of integrated products and services\n\nOptiCell™ to as it continues to transform diagnostics with its suite of integrated products and services The new haematology analyser offers innovative AI-powered technology for CBC analysis, providing lab",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "quality accuracy 1 at the point of care\n\nat the point of care The analyser represents significant time, cost and space savings for veterinarians with minimal maintenance requirements\n\nSYDNEY\n\nSept. 17, 2024\n\nAustralia\n\n/PRNewswire/ -- <em>Zoetis</em> <em>Inc</em>., the world's leading animal health company, is set to unveil its new haematology analyser VetscanOptiCell",
"sentiment": 0.802,
"highlighted_in": "main_text"
},
{
"highlight": "Vetscan OptiCell reaffirms <em>Zoetis</em>' longstanding commitment to advancing veterinary medicine through meaningful innovation.",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "The latest addition to <em>Zoetis</em>' suite of diagnostic products and services offers a more advanced approach to haematology by utilising cell-focusing and AI-powered classification technology for CBC analysis, delivering lab quality accuracy1 at the point of care.",
"sentiment": 0.6666,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Zoetis</em> to Introduce First Cartridge-Based AI-Powered Haematology Analyser",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "db0df733-1490-472d-9657-ade3cda109e2",
"title": "Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy",
"description": "-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to...",
"keywords": "Nasdaq:CAPR, Capricor Therapeutics",
"snippet": "-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Mi...",
"url": "https://www.globenewswire.com/news-release/2024/09/17/2947526/0/en/Capricor-Therapeutics-Signs-Binding-Term-Sheet-with-Nippon-Shinyaku-for-European-Expansion-and-Commercialization-of-Deramiocel-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/16ce4387-5b8f-447c-96b8-7c453633f9bf",
"language": "en",
"published_at": "2024-09-17T13:15:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "CAPR",
"name": "Capricor Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 72.50299,
"sentiment_score": 0.21015,
"highlights": [
{
"highlight": "Milestones and a Double-Digit Percentage of Product Revenue-\n\n\n\n-Upfront Payment and Investment Extends Cash Runway into 2026-\n\n-Potential Milestones from Combined Distribution Agreements Now Total approximately $1.5 Billion-\n\n-Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel-\n\nSAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- <em>Capricor</em>",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Therapeutics</em> (<em>NASDAQ</em>: <em>CAPR</em>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced it has entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company listed on the TYO, for the commercialization and distribution in Europe of Capricor",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Capricor</em> <em>Therapeutics</em>\n\n<em>Capricor</em> <em>Therapeutics</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>CAPR</em>) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Capricor</em> <em>Therapeutics</em> Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "4516.T",
"name": "Nippon Shinyaku Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "jp",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.067287,
"sentiment_score": 0.332067,
"highlights": [
{
"highlight": "Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel-\n\nSAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced it has entered into a binding term sheet with <em>Nippon</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Shinyaku</em> <em>Co</em>., <em>Ltd</em>., a Japanese pharmaceutical company listed on the TYO, for the commercialization and distribution in Europe of Capricor’s lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD), a rare neuromuscular disease with limited treatment options.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with <em>Nippon</em> <em>Shinyaku</em> <em>Co</em>., <em>Ltd</em>. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications.",
"sentiment": 0.8431,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NPPNY",
"name": "Nippon Shinyaku Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 44.70363,
"sentiment_score": 0.332067,
"highlights": [
{
"highlight": "Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel-\n\nSAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced it has entered into a binding term sheet with <em>Nippon</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Shinyaku</em> <em>Co</em>., <em>Ltd</em>., a Japanese pharmaceutical company listed on the TYO, for the commercialization and distribution in Europe of Capricor’s lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD), a rare neuromuscular disease with limited treatment options.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with <em>Nippon</em> <em>Shinyaku</em> <em>Co</em>., <em>Ltd</em>. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications.",
"sentiment": 0.8431,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "63411b77-e2be-4175-8b6e-c8934e271380",
"title": "Teladoc stock spikes as Jefferies boosts target (NYSE:TDOC)",
"description": "Teladoc Health (TDOC) stock rose 7% premarket after Jefferies cited a short-term opportunity in the telehealth provider based on web traffic data. Read more here.",
"keywords": "",
"snippet": "Shares of Teladoc Health (NYSE:TDOC) rose ~7% premarket Tuesday after Jefferies cited a short-term opportunity in the telehealth provider following an analysis ...",
"url": "https://seekingalpha.com/news/4150293-teladoc-stock-spikes-jefferies-boosts-target",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185318210/image_185318210.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2024-09-17T13:03:35.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "TDOC",
"name": "Teladoc Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 64.07102,
"sentiment_score": 0.4653,
"highlights": [
{
"highlight": "Shares of <em>Teladoc</em> <em>Health</em> (<em>NYSE:TDOC</em>) rose ~7% premarket Tuesday after Jefferies cited a short-term opportunity in the telehealth provider following an analysis of web traffic data related to the company's mental health business, BetterHelp.\n\nDespite a Hold rating on the stock, the brokerage",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "Teladoc stock spikes as Jefferies boosts target (<em>NYSE:TDOC</em>)",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "93a42544-24fe-4010-9b9a-9b085307c717",
"title": "Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying - Exicure (NASDAQ:XCUR)",
"description": "",
"keywords": "",
"snippet": "The Dow Jones index closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the compa...",
"url": "https://www.benzinga.com/markets/penny-stocks/24/09/40898685/reneo-pharmaceuticals-and-2-other-stocks-under-5-executives-are-buying",
"image_url": "https://cdn.benzinga.com/files/images/story/2024/09/17/3-azioni-a-basso-prezzo-da-tenere-docchi.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-09-17T13:01:02.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "XCUR",
"name": "Exicure, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 103.49485,
"sentiment_score": 0.24515,
"highlights": [
{
"highlight": "<em>Exicure</em>\n\nThe Trade: <em>Exicure</em>, <em>Inc</em>. XCUR 10% owner DGP Co., Ltd. bought a total of 237,223 shares at an average price of $3.00. To acquire these shares, it cost around $711,669.\n\n10% owner DGP Co., Ltd. bought a total of 237,223 shares at an average price of $3.00. To acquire these shares, it cost around $711,669.",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "What's Happening: On Sept. 13, <em>Exicure</em> entered into debt-for-equity exchange agreements..\n\nOn Sept. 13, <em>Exicure</em> entered into debt-for-equity exchange agreements..",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "What <em>Exicure</em> Does: <em>Exicure</em> <em>Inc</em> is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss.\n\nAmylyx Pharmaceuticals\n\nThe Trade: Amylyx Pharmaceuticals, Inc. AMLX CFO James M Frates acquired a total of 40,000 shares at an average price of $2.53.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying - <em>Exicure</em> (<em>NASDAQ:XCUR</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "RPHM",
"name": "Reneo Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 109.01723,
"sentiment_score": 0.007033,
"highlights": [
{
"highlight": "<em>Reneo</em> <em>Pharmaceuticals</em>\n\nThe Trade: <em>Reneo</em> <em>Pharmaceuticals</em>, <em>Inc</em>. <em>RPHM</em> 10% owner Braden Michael Leonard acquired a total of 358,923 shares at an average price of $1.35. The insider spent around $484,344 to buy those shares.\n\n10% owner Braden Michael Leonard acquired a total of 358,923 shares at an average price of $1.35.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "What's Happening: On Aug. 13, <em>Reneo</em> <em>Pharmaceuticals</em> reported quarterly losses of 16 cents per share..\n\nOn Aug. 13, <em>Reneo</em> <em>Pharmaceuticals</em> reported quarterly losses of 16 cents per share.. What <em>Reneo</em> <em>Pharmaceuticals</em> Does: <em>Reneo</em> <em>Pharmaceuticals</em> <em>Inc</em> is a clinical-stage pharmaceutical company.\n\nRead More:",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Reneo</em> <em>Pharmaceuticals</em> And 2 Other Stocks Under $5 Executives Are Buying - Exicure (NASDAQ:XCUR)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 687,
"sentiment_avg": 0.2153253379577996
}
]
}
Other details
Entity count
- 11,338